Akebia Therapeutics (AKBA) Receivables - Net (2013 - 2026)
Akebia Therapeutics (AKBA) posted quarterly Receivables - Net of $62.5 million for Q1 2026, up 1.62% year-over-year from $61.5 million in Q1 2025, and up 32.97% quarter-over-quarter from $47.0 million in Q4 2025.
Akebia Therapeutics (AKBA) Receivables - Net (2013 - 2026) Analysis & Trends
Akebia Therapeutics (AKBA) has reported Receivables - Net for 14 consecutive years, with $62.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Receivables - Net rose 1.62% year-over-year to $62.5 million; the TTM figure through Mar 2026 stood at $62.5 million (up 1.62% YoY), while the FY2025 annual figure was $47.0 million, up 36.85% from the prior year.
- Receivables - Net climbed to $62.5 million in Q1 2026 per AKBA's latest filing, from $47.0 million in the prior quarter.
- Across five years, Receivables - Net topped out at $82.0 million in Q2 2022 and bottomed at $18.7 million in Q1 2023.
- Historically, Receivables - Net has averaged $43.8 million across 5 years, with a median of $39.3 million in 2023.
- Annual changes were most pronounced in 2022 — Receivables - Net surged 5654.86% — and 2023, when it tumbled 76.13%.
- Akebia Therapeutics' Receivables - Net stood at $40.3 million in 2022, then decreased by 2.47% to $39.3 million in 2023, then dropped by 12.53% to $34.4 million in 2024, then surged by 36.85% to $47.0 million in 2025, then surged by 32.97% to $62.5 million in 2026.
- Business Quant data shows AKBA's Receivables - Net at $62.5 million in Q1 2026, $47.0 million in Q4 2025, and $66.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.85 Bn | 42.88 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.02 Bn | 39.37 Bn | 2.15 Bn |
| 3 | Zoetis | 31.47 Bn | 29.79 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.59 Bn | 22.79 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.20 Bn | 19.53 Bn | 683.80 Mn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.45 Bn | 15.06 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - |
| 10 | Akebia Therapeutics | 248.20 Mn | 92.65 Mn | 38.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 53.51 Mn |
| Jun 30, 2026 | 53.51 Mn |
| Mar 31, 2026 | 62.54 Mn |
| Mar 31, 2026 | 62.54 Mn |
| Dec 31, 2025 | 47.03 Mn |
| Dec 31, 2025 | 47.03 Mn |
| Sep 30, 2025 | 66.22 Mn |
| Sep 30, 2025 | 66.22 Mn |
| Jun 30, 2025 | 72.81 Mn |
| Jun 30, 2025 | 72.81 Mn |
| Mar 31, 2025 | 61.54 Mn |
| Mar 31, 2025 | 61.54 Mn |
| Dec 31, 2024 | 34.37 Mn |
| Dec 31, 2024 | 34.37 Mn |
| Sep 30, 2024 | 32.17 Mn |
| Sep 30, 2024 | 32.17 Mn |
| Jun 30, 2024 | 29.77 Mn |
| Jun 30, 2024 | 29.77 Mn |
| Mar 31, 2024 | 26.62 Mn |
| Mar 31, 2024 | 26.62 Mn |